Form 4: Regulus Therapeutics Director Collier Acquires 4,000 Shares

Director Kathryn J. Collier of Regulus Therapeutics Inc. [RGLS] purchased 4,000 shares of common stock at $1.82 per share on July 25, 2024.

Summary

• On July 25, 2024, Kathryn J. Collier, a director of Regulus Therapeutics Inc. (RGLS), acquired 4,000 shares of common stock.
• The purchase price was $1.82 per share.
• Following the transaction, Collier directly owns 6,740 shares of Regulus Therapeutics Inc.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. A director purchasing shares suggests confidence, but the scale of the purchase is not significant enough to indicate a strong positive sentiment.

Positives

• A director's purchase of company stock can be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

Form 4 filings are standard disclosures required by the SEC when insiders (officers, directors, or those holding more than 10% of a company's shares) buy or sell their company's stock. These filings are closely watched by investors for signals about management's view of the company's prospects.

Stakeholder Impact

• The purchase could have a minor positive impact on shareholder sentiment.

Key Dates